Body mass index–based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease

[1] Younossi Z(2018)Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 15 11-20

[2] Anstee QM(2009)American Association for the Study of Liver Diseases Liver Biopsy Hepatology 49 1017-1044

[3] Marietti M(2017)Individual patient data meta-analysis of Controlled Attenuation Parameter (CAP) technology for assessing steatosis J Hepatol 66 1022-1030

[4] Rockey DC(2013)Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B J Gastroenterol Hepatol 28 1738-1745

[5] Caldwell SH(2019)Controlled attenuation parameter for assessment of hepatic steatosis in Indian patients J Clin Exp Hepatol. 9 13-21

[6] Goodman ZD(2019)Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography J Clin Exp Hepatol 9 207-214

[7] Karlas T(2017)Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease Gastroenterology 152 598-607.e2

[8] Petroff D(2017)American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases Gastroenterology. 152 1544-1577

[9] Sasso M(2012)The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology. 142 1592-1609

[10] Goyal R(2018)Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients Surg Obes Relat Dis 14 81-91

[1] Younossi Z(2018)Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 15 11-20

[2] Anstee QM(2009)American Association for the Study of Liver Diseases Liver Biopsy Hepatology 49 1017-1044

[3] Marietti M(2017)Individual patient data meta-analysis of Controlled Attenuation Parameter (CAP) technology for assessing steatosis J Hepatol 66 1022-1030

[4] Rockey DC(2013)Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B J Gastroenterol Hepatol 28 1738-1745

[5] Caldwell SH(2019)Controlled attenuation parameter for assessment of hepatic steatosis in Indian patients J Clin Exp Hepatol. 9 13-21

[6] Goodman ZD(2019)Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography J Clin Exp Hepatol 9 207-214

[7] Karlas T(2017)Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease Gastroenterology 152 598-607.e2

[8] Petroff D(2017)American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases Gastroenterology. 152 1544-1577

[9] Sasso M(2012)The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology. 142 1592-1609

[10] Goyal R(2018)Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients Surg Obes Relat Dis 14 81-91